37. 膿疱性乾癬（汎発型） Generalised pustular psoriasis Clinical trials / Disease details
臨床試験数 : 79 / 薬物数 : 57 - (DrugBank : 21) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-184065 | 22/8/2018 | 15/08/2018 | I6T-MC-AMAJ | A Multicenter Randomized Double-Blind Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis OASIS-2 | Psoriasis valgaris, Generalized pustular psoriasis, Erythrodermic psoriasis | Intervention name : LY3074828 INN of the intervention : mirikizumab Dosage And administration of the intervention : Administered subcutaneous injection Control intervention name : Secukinumab INN of the control intervention : secukinumab Dosage And administration of the control intervention : Administered subcutaneous injection Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Administered subcutaneous injection | Eli Lilly Japan K.K. | NULL | complete | 20 | BOTH | 120 | Phase 3 | Japan, Asia except Japan, North America, South America, Europe, Oceania |